Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TD-4208

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Revefenacin (TD-4208) is a potent, lung-selective, long-acting muscarinic antagonist currently in development as a… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2018
2018
Abstract Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
ABSTRACT Introduction: Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para… Expand
Is this relevant?
2014
2014
Introduction TD-4208 is a lung-selective, LAMA shown to have a long duration of action and minimal systemic antimuscarinic… Expand
Is this relevant?
2013
2013
Tiotropium is currently the only once-daily, long-acting muscarinic antagonist (LAMA) approved in the United States and other… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
Review
2013
Review
2013
The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary disease (COPD) is well established… Expand
Is this relevant?
2012
2012
Background: TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration in… Expand
Is this relevant?